Plasma phospholipids identify antecedent memory impairment in older adults

By M. Mapstone, A. Cheema, M. Fiandaca, X. Zhong, T. Mhyre, Linda Macarthur, W. Hall, S. Fisher, Derick R. Peterson, J. Haley and 7 more. Nature Medicine, 2014

990 citations recorded by the source corpus.

Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progressed to produce evident memory loss and functional decline. Biomarkers of preclinical disease will be critical to the development of disease-modifying or even preventative therapies. Unfortunately, current biomarkers for early disease, including cerebrospinal fluid tau and amyloid-β levels, structural and functional magnetic resonance imaging and the recent use of brain amyloid imaging or inflammaging, are limited because they are either invasive, time-consuming or expensive. Blood-based biomarkers may be a more attractive option, but none can currently detect preclinical Alzheimer's disease with the required sensitivity and specificity. Herein, we describe our lipidomic approach to detecting preclinical Alzheimer's disease in a group of cognitively normal older adults. We discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2–3 year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/697798bce4cf2f39ba6bdc01da8e9dd9ef46f1f7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Physiology

Citations in the corpus

Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, background): “As a result, these markers are not yet ready for clinical application [227,232] as they have not yet been evaluated specifically within the context for which they are intended (i.”
Identification of pre-clinical Alzheimer’s disease by a profile of pathogenic proteins in neurally-derived blood exosomes: a case-control study (2014, methodology): “1 year preclinical phase of AD provided a method with 90% accuracy in predicting progression to MCI or mild AD [28].”
An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases (2019, background): “However, other studies have shown that plasma levels of LPC were decreased in patients with Alzheimer’s disease [54,55] and that the LPC-to-PC ratio was also decreased either in plasma or in cerebrospinal fluid from patients with Alzheimer’s disease [56,77].”
Altered Bile Acid Profile Associates with Cognitive Impairment in Alzheimer’s Disease – An Emerging Role for Gut Microbiome (2018, background): “Mapstone and colleagues [39] identified increased levels of glycoursodeoxycholic acid in subjects likely to develop amnestic MCI or AD within 2 to 3 years compared to controls.”